119 related articles for article (PubMed ID: 38655660)
1. Microwave ablation combined with PD-L1 blockade synergistically promotes Cxcl9-mediated antitumor immunity.
He N; Huang H; Wu S; Ji W; Tai Y; Gao R; Liu Y; Liu Y; Chen L; Zhu D; Zheng X; Jiang J
Cancer Sci; 2024 Apr; ():. PubMed ID: 38655660
[TBL] [Abstract][Full Text] [Related]
2. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
[TBL] [Abstract][Full Text] [Related]
3. LAG3 blockade coordinates with microwave ablation to promote CD8
Shao D; Chen Y; Huang H; Liu Y; Chen J; Zhu D; Zheng X; Chen L; Jiang J
J Transl Med; 2022 Sep; 20(1):433. PubMed ID: 36180876
[TBL] [Abstract][Full Text] [Related]
4. TIGIT Blockade Exerts Synergistic Effects on Microwave Ablation Against Cancer.
Chen Y; Huang H; Li Y; Xiao W; Liu Y; Chen R; Zhu Y; Zheng X; Wu C; Chen L
Front Immunol; 2022; 13():832230. PubMed ID: 35320940
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antitumor efficacy through microwave ablation in combination with immune checkpoints blockade in breast cancer: A pre-clinical study in a murine model.
Zhu J; Yu M; Chen L; Kong P; Li L; Ma G; Ge H; Cui Y; Li Z; Pan H; Xie H; Zhou W; Wang S
Diagn Interv Imaging; 2018 Mar; 99(3):135-142. PubMed ID: 29398572
[TBL] [Abstract][Full Text] [Related]
6. Combined use of microwave ablation and cell immunotherapy induces nonspecific immunity of hepatocellular carcinoma model mice.
Duan X; Wang M; Han X; Ren J; Huang G; Ju S; Zhang Q
Cell Cycle; 2020 Dec; 19(24):3595-3607. PubMed ID: 33283623
[TBL] [Abstract][Full Text] [Related]
7. Microwave ablation combined with anti-PD-1/CTLA-4 therapy induces an antitumor immune response to renal cell carcinoma in a murine model.
Guo RQ; Peng JZ; Li YM; Li XG
Cell Cycle; 2023 Jan; 22(2):242-254. PubMed ID: 35980140
[TBL] [Abstract][Full Text] [Related]
8. Programmed death-ligand 1 expression and CD8+ tumor-infiltrating lymphocytes in advanced non-small cell lung cancer treated with microwave ablation and chemotherapy.
Wei Z; Zhan X; Fan L; Ye X; Yang X; Huang G; Li W; Wang J; Han X; Meng M; Ni Y; Li Q
Int J Hyperthermia; 2018; 35(1):591-598. PubMed ID: 30307348
[TBL] [Abstract][Full Text] [Related]
9. Enhancing the therapeutic efficacy of programmed death ligand 1 antibody for metastasized liver cancer by overcoming hepatic immunotolerance in mice.
Xin B; Yang M; Wu P; Du L; Deng X; Hui E; Feng GS
Hepatology; 2022 Sep; 76(3):630-645. PubMed ID: 34860431
[TBL] [Abstract][Full Text] [Related]
10. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
[TBL] [Abstract][Full Text] [Related]
11. Microwave ablation combined with OK-432 induces Th1-type response and specific antitumor immunity in a murine model of breast cancer.
Li L; Wang W; Pan H; Ma G; Shi X; Xie H; Liu X; Ding Q; Zhou W; Wang S
J Transl Med; 2017 Jan; 15(1):23. PubMed ID: 28137271
[TBL] [Abstract][Full Text] [Related]
12. Anti-PD-L1 antibody enhances curative effect of cryoablation
Tan J; Liu T; Fan W; Wei J; Zhu B; Liu Y; Liu L; Zhang X; Chen S; Lin H; Zhang Y; Li J
Acta Pharm Sin B; 2023 Feb; 13(2):632-647. PubMed ID: 36873191
[TBL] [Abstract][Full Text] [Related]
13. Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist.
Knudson KM; Hicks KC; Ozawa Y; Schlom J; Gameiro SR
J Immunother Cancer; 2020 Apr; 8(1):. PubMed ID: 32303618
[TBL] [Abstract][Full Text] [Related]
14. Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells.
Tu J; Xu H; Ma L; Li C; Qin W; Chen X; Yi M; Sun L; Liu B; Yuan X
Theranostics; 2022; 12(2):747-766. PubMed ID: 34976211
[No Abstract] [Full Text] [Related]
15. CD4
Xiao M; Xie L; Cao G; Lei S; Wang P; Wei Z; Luo Y; Fang J; Yang X; Huang Q; Xu L; Guo J; Wen S; Wang Z; Wu Q; Tang J; Wang L; Chen X; Chen C; Zhang Y; Yao W; Ye J; He R; Huang J; Ye L
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35580929
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine-facilitated modulation of the tumor microenvironment and PD-1/PD-L1 blockade generate a synergistic antitumor effect in a murine hepatocellular carcinoma model.
Wang H; He X; Fang D; Wang X; Guan J; Shi ZW; Chen X
Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101853. PubMed ID: 34923183
[TBL] [Abstract][Full Text] [Related]
17. Microwave ablation combined with anti-PD-1 therapy enhances systemic antitumor immunity in a multitumor murine model of Hepa1-6.
Huang S; Li T; Chen Y; Liu J; Wang Y; Yang C; Wang C; Ju S; Bai Y; Yao W; Xiong B
Int J Hyperthermia; 2022; 39(1):278-286. PubMed ID: 35129044
[TBL] [Abstract][Full Text] [Related]
18. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
19. Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10.
Bergamaschi C; Pandit H; Nagy BA; Stellas D; Jensen SM; Bear J; Cam M; Valentin A; Fox BA; Felber BK; Pavlakis GN
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461349
[TBL] [Abstract][Full Text] [Related]
20. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]